mediate insulins are used to supply basal insulin requirements. A variation of 25% around a half time of 14 hours means that the same dose of insulin may produce hypoglycaemia on one day and good control or hyperglycaemia the next. Thus, the overnight period is the Achilles's heel of conventional insulin treatment,l5 and much of the minor adjustment of dosage is probably futile. The intermediate insulins are not precision tools.
Since the rate of absorption of NPH insulin depends on the dose the time scatter, and hence the unpredictability of clinical effect, will increase with the size of dose. This explains the success of treatment schedules based on multiple injections of soluble insulin during the day with small doses of NPH insulin last thing at night.16 Soluble and intermediate insulin treatment given twice daily is not necessarily the treatment of choice for young insulin-dependent patients, and alternative regimens must be found if conventional treatment is to meet the challenge of portable infusion devices.
Introduction Graft-versus-host disease is a major complication of bone marrow transplantation. The disease is not completely understood but appears to be initiated by mature donor T lymphocytes. ' The new immunosuppressive agent cyclosporin A, which prevents clonal expansion of T lymphocytes after primary antigen challenge,2 was found to reduce the morbidity and mortality associated with graft-versus-host disease when compared with methotrexate used as-prophylaxis. 3 In man the dose of cyclosporin A is limited by renal toxicity as well as by other, less severe side effects.6 8 Few data are available on the absorption of oral preparations of the drug after bone marrow transplantation and the relation between blood 
Patients and methods
The procedure for bone marrow transplantation was as described.9 All patients were managed in protective isolation during the period of neutropenia. Table I 17 JULY 1982 below 100 ,ug/l in patients with graft-versus-host disease not responding to steroids the dose was increased by up to twofold until control was achieved. Two patients with concentrations below 100 ,Ag/l were given the drug intravenously; failure of absorption was suspected due to severe diarrhoea and vomiting. When blood concentrations of cyclosporin A exceeded 1000 ,tg/l or hypertension, convulsions, severe fluid overload, or rapidly rising blood urea concentrations or values greater than 10 mmol/l (60 mg/100 ml) occurred, the next dose was omitted and the drug restarted at half to three-quarters of the dose. "Acceptable" side effects when the dose was not reduced included tremor, hirsuties, mild facial oedema, anorexia, and controllable hypertension. Acute graft-versus-host disease-Skin graft-versus-host disease was diagnosed by a characteristic rash over the face, palms, and extensor surfaces, spreading to the trunk, and associated with compatible changes on skin biopsy."' Gastrointestinal graft-versus-host disease was diagnosed by diarrhoea (six or more stools/day) and vomiting, gut cramps, anorexia, and, in some cases, rectal or jejunal biopsy. Liver graft-versus-host disease was diagnosed when the alkaline phosphatase activity rose over 500 IU in the presence of raised alanine and aspartate transaminase activities. Acute graft-versus-host disease was treated (after other causes of fever and rashes had been excluded) with methylprednisolone 1 g/m2 for three days, with dose reduction over 10-14 days in more severe cases. Repeat courses were given for relapse of symptoms.9
Chronic skin graft-versus-host disease was diagnosed by lichenplanus-like lesions in the mouth and tongue and lichen planopilaris lesions on the trunk and limbs associated with a lymphocytic infiltrate on skin biopsy.'2 Chronic reactions were treated with oral prednisolone 15 mg/m2/day with or without azathioprine 25 mg/m2/day. Treatment was withdrawn on disappearance of symptoms.
Results
Outcome after transplantation-Twenty-six of the 36 patients were alive 72-626 days after transplantation ( (fig 3) . Patients with severe aplastic anaemia differed from the others in achieving large and rapid rises in blood cyclosporin A concentrations after transplantation, but only one patient developed serious toxicity necessi-165 administration was started 10 days before transplantation (schedule IV) high blood concentrations were achieved in the first 15 days after transplantation. At day 10 after operation patients given schedule IV had mean concentrations of 245 ,ug/l compared with a mean of 150 ltg/l in patients given schedules I, II and III. Figure 5 shows the results with the four schedules (patients with mismatched grafts are excluded since they were not evenly distributed through the different schedules). There was no significant difference in the incidence or severity of acute or chronic graft-versus-host disease in any schedule. Toxicity was a major feature of schedule II: four of the six patients developed renal failure, and two died from a combination of renal failure and lung complications. Because of these complications only six patients were treated with this schedule. Toxicity cyclosporin A is more effective at preventing graft-versus-host disease if it is present in measurable amounts in the blood on the day of transplantation. Arguably, however, higher doses are necessary to prevent the complication, but toxicity is a limiting factor. Common to all schedules were low blood concentrations of the drug around 15 days after operation, suggesting that the chemotherapy and radiotherapy before transplantation temporarily affected gastrointestinal absorption of the drug. This erratic absorption may be a major obstacle to using oral cyclosporin A to prevent graft-versus-host disease.
The duration of treatment with cyclosporin A needed to protect against graft-versus-host disease is controversial. Other groups have given the drug for up to one year after transplantation. 4 We decided to stop cyclosporin A after 100 days, since we find that acute graft-versus-host disease does not occur after this time in patients given methotrexate. In our first patient given cyclosporin A an acute graft-versus-host reaction occurred when the drug was stopped abruptly, hence where possible the dose was tailed off over 30-40 days in subsequent patients. This resulted in only two patients developing the chronic reaction after stopping cyclosporin A. In several patients, however, the drug was stopped abruptly or reduced before 100 days because of toxicity; and in patients with mismatched grafts persisting chronic graft-versus-host disease necessitated continued treatment past 100 days.
In conclusion our results show that cyclosporin A plays a major part in preventing the serious consequences of graftversus-host disease. While toxicity may be largely avoided by careful monitoring of drug concentrations, blood urea values, and blood pressure, manipulating the oral dose within the limits of toxicity is unlikely to be associated with improved prophylaxis against the complication.
Further improvements in preventing graft-versus-host disease may be achieved only by using parenteral cyclosporin A or by combining this drug with other techniques for preventing the complication, such as eliminating mature T lymphocytes
